Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KM1 oncolytic vaccinia virus plus sintilimab in advanced solid tumors
CTR20260070Phase 2Active
- Sponsor
- Huayao Kangming
- Start
- Mar 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Oncolytic Viruses → Oncolytic Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of KM1, sintilimab in Nonhematologic neoplasms, soft tissue sarcoma (STS), synovial sarcoma (SS), Bone and soft tissue sarcoma, Liposarcoma, sponsored by Huayao Kangming. Started Mar 2026; status: active.
02
Drugs
KM1sintilimab
03
Conditions
Nonhematologic neoplasmssoft tissue sarcoma (STS)synovial sarcoma (SS)Bone and soft tissue sarcomaLiposarcoma
Beyond the preview
Go deeper on CTR20260070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260070.